Heimall, Jennifer R.
Hagin, David
Hajjar, Joud
Henrickson, Sarah E.
Hernandez-Trujillo, Hillary S.
Tan, Yuval
Kobrynski, Lisa
Paris, Kenneth
Torgerson, Troy R.
Verbsky, James W.
Wasserman, Richard L.
Hsieh, Elena W. Y.
Blessing, Jack J.
Chou, Janet S.
Lawrence, Monica G.
Marsh, Rebecca A.
Rosenzweig, Sergio D.
Orange, Jordan S.
Abraham, Roshini S.
Funding for this research was provided by:
National Institutes of Health (T32: 5T32HD043021-12)
National Institutes of Health (K12: K12HD043245)
Article History
Received: 10 November 2017
Accepted: 16 March 2018
First Online: 19 April 2018
Change Date: 21 May 2018
Change Type: Correction
Change Details: The original version of this article unfortunately contained mistakes in some of the author names and affiliations. The correct list of author names and affiliations is below, with the corrections in <b>bold</b>.
Compliance with Ethical Standards
:
: The authors declared that they have no conflict of interest, except for the following:Jennifer Heimall, MD: ADMA Consultant; CSL Behring speaker panelSarah Henrickson, MD, PhD: Horizon Pharmaceuticals advisory boardKenneth Paris, MD, MPH: Shire Advisory Board Participant, Speaker, Clinical Trial Investigator; CSL Behring Advisory Board ParticipantTroy Torgerson, MD, PhD: Director Seattle Children’s Immunology Diagnostic Lab, Seattle, WAJordan Orange, MD, PhD: Shire Consultant, Grifols Consultant